返回 
加入收藏
地舒单抗和特立帕肽治疗中国女性绝经后骨质疏松症的成本-效用分析
x
请在关注微信后，向客服人员索取文件
| 篇名： | 地舒单抗和特立帕肽治疗中国女性绝经后骨质疏松症的成本-效用分析 |
| TITLE： | Cost-utility analysis of denosumab and teriparatide in the treatment of postmenopausal osteoporosis in Chinese women |
| 摘要： | 目的 评价地舒单抗和特立帕肽治疗中国女性绝经后骨质疏松症的经济性，为相关决策提供参考。方法从我国医疗卫生体系角度出发，利用Excel2003软件建立马尔科夫模型，采用成本-效用分析法评价地舒单抗和特立帕肽分别联合碳酸钙D3片治疗中国女性绝经后骨质疏松症的经济性。药物治疗效果来自网状荟萃结果，成本和健康效用值数据来自已发表的文献。模型的循环周期为1年，模拟时限为患者终身。采用单因素敏感性分析和概率敏感性分析评价模型参数变化对结果稳健性的影响；并通过情境分析探讨特立帕肽组采用国产药的药品成本的经济性，特立帕肽组药物后遗效应对结果的影响以及特立帕肽停药后序贯使用地舒单抗治疗的经济性。结果地舒单抗方案的效果优于特立帕肽方案[13.24质量调整生命年（QALYs）vs.12.96QALYs]，同时其成本也更低（51224.64元vs.167102.67元），地舒单抗方案为绝对优势方案。单因素敏感性分析结果显示，特立帕肽注射液的成本和贴现率对结果的影响较大。概率敏感性分析结果显示，使用3倍我国2021年人均国内生产总值作为意愿支付阈值时，地舒单抗方案具有经济性的概率为93.5%。情境分析结果显示，无论特立帕肽方案换用国产药的药品成本，还是考虑特立帕肽的药物后遗效应，又或是特立帕肽用药2年后序贯使用地舒单抗治疗，地舒单抗方案都是绝对优势方案。结论地舒单抗联合碳酸钙D3片治疗中国女性绝经后骨质疏松症较特立帕肽联合碳酸钙D3片更具经济性。 |
| ABSTRACT： | OBJECTIVE To evaluate the cost-effectiveness of denosumab and teriparatide in the treatment of postmenopausal osteoporosis in Chinese women， and provide reference for relevant decision-making. METHODS From the perspective of health system in China， Excel 2003 was used to establish Markov model， and cost-utility analysis was used to evaluate the cost- effectiveness of denosumab or teriparatide combined with Calcium carbonate D3 tablets in the treatment of postmenopausal osteoporosis in Chinese women. Pharmacotherapy effects were obtained with network meta-analysis， and cost and health utility value data were obtained from published literature. The model cycle was 1 year， and the simulation time limit was the patient’s lifetime. Univariate sensitivity analysis and probabilistic sensitivity analysis were used to evaluate the effects of model parameter changes on the robustness of the results. Through scenario analysis， the cost-effectiveness of domestic drug cost used as drug cost of terlipatide group was discussed； the influence of residual effects of teriparatide on the results and the cost-effectiveness of sequential use of desumamab after terlipatide withdrawal were also discussed. RESULTS The effect of denosumab regimen was better than that of terlipatide regimen [13.24 quality-adjusted life years （QALYs） vs. 12.96 QALYs]， with lower cost （51 224.64 yuan vs. 167 102.67 yuan）， denosumab regimen was the absolutely superior regimen. The results of single factor sensitivity analysis showed that the cost and discount rate of Terlipatide injection had greater impact on the results. The results of probability sensitivity analysis showed that when three times of China’s per capita gross domestic product （GDP） in 2021 was used as the threshold of willingness to pay， the probability of cost-effectiveness of denosumab regimen was 93.5%. The results of scenario analysis showed that， whether the drug cost of terlipatide regimen which was replaced by domestic drugs， or the residual effect of terlipatide was considered， or desulmonab was used sequentially after two years of terlipide treatment， denosumab regimen was always the absolute advantage regimen. CONCLUSIONS Denosumab combined with Calcium carbonate D3 tablets is more cost-effective than teriparatide combined with Calcium carbonate D3 tablets in the treatment of postmenopausal osteoporosis in Chinese women. |
| 期刊： | 2023年第34卷第02期 |
| 作者： | 杜桂平；李玉坤；李敏；薛鹏；刘岩；刘国强 |
| AUTHORS： | DU Guiping，LI Yukun，LI Min，XUE Peng，LIU Yan，LIU Guoqiang |
| 关键字： | 地舒单抗；特立帕肽；中国女性；绝经后骨质疏松症；成本-效用分析 |
| KEYWORDS： | densumab； teriparatide； Chinese women； postmenopausal osteoporosis； cost-utility analysis |
| 阅读数： | 259 次 |
| 本月下载数： | 11 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
